Antineuronal Nuclear Antibody Type 3 (ANNA-3) Titer, Serum
Use
Evaluating patients who present with a subacute neurological disorder of undetermined etiology and have risk factors for primary lung carcinoma. ANNA-3 is an IgG marker of an immune response to small-cell lung carcinoma (SCLC) in patients presenting with a subacute, usually multifocal, paraneoplastic neurologic disorder. Paraneoplastic sensorimotor neuropathy, cerebellar ataxia, and limbic encephalopathy are the most common presentations.
Special Instructions
This test is only orderable as a reflex and is performed at an additional charge if the indirect immunofluorescence pattern suggests antineuronal nuclear antibody type 3 (ANNA-3).
Limitations
Antineuronal nuclear antibody type 3 (ANNA-3) is not detectable when it coexists with ANNA-1 or ANNA-2 unless its titer exceeds that of coexisting neuronal nuclear antibodies or is demonstrable by Western blot. It has not yet been encountered in healthy subjects or patients with lung carcinoma without a neurological accompaniment or with other cancers.
New York Approved
Methodology
Immunoassay (Indirect Immunofluorescence Assay (IFA))
Biomarkers
LOINC Codes
- 94344-9
- 94344-9
Result Turnaround Time
5-8 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
Not provided
Minimum Volume
0.6 mL
Collection Instructions
Not explicitly provided; only orderable as a reflex from specific evaluations.
Causes for Rejection
Gross hemolysis, gross lipemia, gross icterus
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 72 hours |
| Refrigerated | 28 days |
| Frozen | 28 days |